Traws Pharma Shares Drop After UK Regulator Delays Mid-Stage Flu Trial
Traws Pharma's stock plunged in premarket trading following a late-Friday disclosure that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) issued a negative review that defers a planned mid-stage human challenge study of tivoxavir marboxil. The setback follows an earlier FDA clinical hold in the U.S. tied to mutagenicity concerns. …